Abdullah TAŞKIN, Selen İLHAN ALP, Şahbettin SELEK, Recep ALP

Relationship between PON1 phenotype and headache duration in migraine patients

The available data on the activity of paraoxonase-1 (PON1) in patients suffering from migraine without aura (MWoA) is scarce. The present study was conducted to fulfill the objective of investigating the probability of an association between PON1 phenotype distribution and headache duration in patients suffering from MWoA. Materials and methods: Seventy-six patients who suffer from MWoA and were not experiencing attacks at the time and 65 healthy volunteers were enrolled for the purpose of evaluation in the present study. Results: The levels of serum paraoxonase, arylesterase activities, and lipid hydroperoxide (LOOH) were determined for these subjects. The results obtained revealed that no statistical differences existed between the group suffering from MWoA and the control group with respect to the PON1 activity and the phenotype distribution (all values of P > 0.05), while the levels of serum LOOH were noted to be higher (P < 0.05) in the patient group. However, a significant relation was found between the PON1192QR phenotype distribution and headache duration in patients suffering from MWoA (P < 0.001). It was observed that patients with the PON1192QR (BB = homozygous high activity) polymorphism had headaches of shorter duration than patients with the PON1192QQ (AA = homozygous low activity) and PON1192QR (AB = heterozygous intermediate activity) polymorphisms. Along with these results, significant negative correlations were found between the ratio of salt-stimulated paraoxonase/arylesterase and headache duration (r: -0.40, P < 0.001) in patients suffering from MWoA in comparison to the control group. Finally, the activities of both paraoxonase and arylesterase were found to be inversely correlated with the levels of serum LOOH in the patient group [(r: -0.23, P < 0.05) and (r: -0.27, P < 0.05), respectively]. Conclusion: The results ascertained through the present study suggest that a significant correlation exists between PON1 phenotype distribution and headache duration in patients suffering from MWoA. Additionally, to the best of our knowledge, this is the first study to evaluate the association between PON1 polymorphism and headache duration in patients with migraine. PON1 phenotype distribution will play a key role in headache duration in patients with migraine.

Anahtar Kelimeler:

Key words: Paraoxonase, arylesterase, phenotype, lipid hydroperoxide

Relationship between PON1 phenotype and headache duration in migraine patients

Keywords:

Key words: Paraoxonase, arylesterase, phenotype, lipid hydroperoxide,

PDF

___

Just S, Arndt K, Weiser T, Doods H. Pathophysiology of migraine: A role for neoropeptides. Drug Discovery Today. Disease Mechanism/Pain 2006; 3: 327-33.
Hamed SA. Th e vascular risk associations with migraine: Relation to migraine susceptibility and progression. Atherosclerosis 2009; 205: 15-22. 8. Scher AI, Terwindt GM, Picavet HS, Verscehuren WM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 2005; 22: 614-20. 9. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet 1990; 336: 837-9.
Aslan M, Horoz M, Nazligul Y, Bolukbas C, Bolukbas F, Selek S et al. Serum paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis. Int J Clin Pract 2008; 62: 1050-5.
Selek S, Cosar N, Kocyigit A, Erel O, Aksoy N, Gencer M et al. PON1 activity and total oxidant status in patients with active pulmonary tuberculosis. Clinical Biochemistry 2008; 41: 140- 4.
Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress and macrophage foam cell formation during atherosclerosis development. Free Radic Biol 2004; 37: 1304- 16.
Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183: 349-54.
Graner M, James R.W, Kahri J, Nieminen M.S, Syvanne M, Taskinen M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006; 47: 2429-35.
Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P et al. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 2001; 79: 449-58.
Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron defi ciency anemia. Atherosclerosis 2007; 191: 397-402
Gur M, Aslan M, Yildiz A, Demirbag R, Yılmaz R, Selek S et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006; 36: 779-87.
Selek S, Aslan M, Horoz M, Gur M. Erel O. Oxidative status and serum PON1 activity in beta-thalassemia minor. Clinical Biochemistry 2007; 40: 287-91.
Kurth T, Gaziano J.M, Cook NR, Bubes V, Logroscino G, Diener HC et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med 2007; 167: 795-801.
Garcia-Martin E, Martinez C, Serrador M, Alonso-Navaro H, Navacerrada F, Agündez J A G et al. Paraoxonase 1 (PON1) polymorphisms and risk for migraine. J Neurol 2010; 257: 1482-5.
Headache Classifi cation Subcommittee of the International Headache Society. Th e International Classifi cation of Headache Disorders: 2nd edition. Cephalalgia 2004; 24: 9-160.
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001; 56: 20-8.
www. relassay.com (Gaziantep, TURKEY)
Arab K, Steghens J.P. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 2004; 325: 158-63.
Leszek B, Wojciech S, Wojciech K, Joanna O-Kuzia. Serum and intra-erythrocyte antioxidant enzymes and lipid peroxides in children with migraine. Pharmacological reports 2008; 60: 542-8.
Yılmaz G, Surer H, Inan LE, Çoşkun Ö, Yücel D. Increased nitrosative and oxidative stress in platelets of migraine patients. Tohoku J Exp: Med 2007; 211: 23-30.
Stefanović A, Stevuljević JK, Spasić S, Vekic J, Bujisić N. Association of oxidative stress and paraoxonase status with PROCAM risk score. Clinical Biochemistry 2009; 42: 617-23.
Costa LG, Furlong CE, editors. Paraoxonase (PON1) in health and disease: basic and clinical aspects. Norwell, MA: Kluwer Academic Publishers; 2002.